Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk TJA
NCT04075526Phase 1Completed
- Sponsor
- NYU Langone Health
- Start
- Oct 2019
- Primary completion
- Jan 2024
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vancomycin and povidone-iodine in periprosthetic joint infection (PJI) (4 arms), sponsored by NYU Langone Health. Primary endpoint: Rate of Periprosthetic Infection (PJI) After Elective Total Joint Arthroplasty at 90 days. Started Oct 2019; status: completed.
02
Drugs
vancomycinpovidone-iodine
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT04075526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04075526.